[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603914":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":23,"studyPopulation":11,"armGroups":24,"interventions":44,"overallOfficials":11,"centralContacts":53,"locations":61,"responsibleParty":103,"collaborators":11,"id":105,"slug":11,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":11,"eligibilityCriteria":110,"healthyVolunteers":106,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":11,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"MBX Biosciences","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Number of participants with Treatment Emergent Adverse Events (TEAEs)",null,"The total duration of study participation for each participant including screening, treatment period, follow-up, and end of study visit will be up to 91 days in Part A, up to 99 days in Part B, and up to 148 days in Part C.",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"TRIPLE",[20,21,22],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","This is a Phase 1, double-blind, placebo-controlled first-in-human study to evaluate the single ascending doses (SAD) and multiple ascending doses (MAD) of MBX 4291 in participants with obesity, who are otherwise generally healthy. Approximately 124 patients aged 18 to 65 years old will be enrolled.",[25,31,35,38],{"label":26,"type":27,"description":28,"interventionNames":29},"MBX 4291 (Part A)","EXPERIMENTAL","Participants will be administered single ascending doses of MBX 4291, or matching placebo.",[30],"Drug: MBX 4291",{"label":32,"type":27,"description":33,"interventionNames":34},"MBX 4291 (Part B)","Participants will be administered multiple ascending doses of MBX 4291, or matching placebo.",[30],{"label":36,"type":27,"description":33,"interventionNames":37},"MBX 4291 (Part C)",[30],{"label":39,"type":40,"description":41,"interventionNames":42},"Placebo","PLACEBO_COMPARATOR","Participants will be administered single or multiple ascending doses of placebo.",[43],"Drug: Placebo",[45,50],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":11},"DRUG","MBX 4291","MBX 4291 will be administered subcutaneously (SC)",[26,32,36],{"type":46,"name":39,"description":51,"armGroupLabels":52,"otherNames":11},"Placebo: Placebo will be administered subcutaneously (SC)",[39],[54,59],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},"Elisa Fabbrini, MD, PhD","CONTACT","844-877-4473","MBX4291.Clinicaltrials@mbxbio.com",{"name":60,"role":56,"phone":57,"phoneExt":11,"email":58},"Stewart Hallett",[62,76,85,94],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":11},"MBX Biosciences Investigational Site","RECRUITING","Doral","Florida","33172","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-80.35533,25.81954,{"lat":74,"lon":73},{"facility":63,"status":64,"city":77,"state":78,"zip":79,"country":68,"countryCode":69,"cosmosGeoPoint":80,"geoPoint":84,"contacts":11},"Lexington","Kentucky","40509",{"type":71,"coordinates":81},[82,83],-84.47772,37.98869,{"lat":83,"lon":82},{"facility":63,"status":64,"city":86,"state":87,"zip":88,"country":68,"countryCode":69,"cosmosGeoPoint":89,"geoPoint":93,"contacts":11},"Kansas City","Missouri","64114",{"type":71,"coordinates":90},[91,92],-94.57857,39.09973,{"lat":92,"lon":91},{"facility":63,"status":64,"city":95,"state":96,"zip":97,"country":68,"countryCode":69,"cosmosGeoPoint":98,"geoPoint":102,"contacts":11},"Knoxville","Tennessee","37920",{"type":71,"coordinates":99},[100,101],-83.92074,35.96064,{"lat":101,"lon":100},{"type":104,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100603914",false,"NCT07142707","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity","A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity","Inclusion Criteria:\n\n* Age of \\>18 to ≤65 years at the time of signing the informed consent.\n* Has a BMI of ≥30 to \\\u003C50 kg\u002Fm2 at screening and baseline.\n* Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.\n\nExclusion Criteria:\n\n* History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.\n* History of currently active pancreatitis, type I and type II diabetes.\n* Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.\n* A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.","ALL","18 Years","65 Years",{"count":115,"type":116},124,"ESTIMATED","INTERVENTIONAL",[119],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.",[122],"Obesity",[124,125,126,127],"Body Weight","Body Mass Index","Overweight","Nutrition Disorders","2026-06-08",{"date":130,"type":131},"2026-06-09","ACTUAL",{"date":133,"type":131},"2025-09-03",{"date":135,"type":116},"2026-10-30",{"name":5,"class":6},4]